CEFMAX
LOE Approachingcefmenoxime hydrochloride
NDAINJECTIONINJECTABLE
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFMAX (cefmenoxime hydrochloride) is an injectable third-generation cephalosporin antibiotic approved in 1987. It is indicated for serious bacterial infections requiring parenteral therapy, including respiratory tract, urinary tract, and intra-abdominal infections. The drug works by inhibiting bacterial cell wall synthesis, making it bactericidal against susceptible gram-positive and gram-negative organisms.
LOE Approaching
Mature product approaching loss of exclusivity with moderate competitive pressure (30%); team size likely stabilized or contracting.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Careers on CEFMAX are best suited for professionals seeking stable, operational roles in a mature antibiotic franchise rather than high-growth commercial upside. This is an ideal assignment for specialists in hospital channel management, generics operations, or regulatory maintenance looking for predictable, lower-pressure environments.
Hospital Account ManagerAntimicrobial Stewardship Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.